News

Sanofi’s Sarclisa gains EC approval for multiple myeloma treatment
The European Commission (EC) has granted approval to Sanofi's Sarclisa in combination with a regimen of bortezomib, lenalidomide and dexamethasone (VRd) to treat multiple myeloma in adults. Sarclisa ...
PharmiWeb1d
Sanofi’s Sarclisa approved in the EU for the treatment of transplant-eligible newly diagnosed multiple myeloma
Sanofi’s Sarclisa approved in the EU for the treatment of transplant-eligible newly diagnosed multiple myeloma  Approval based on GMMG-HD7 phase 3 study demonstrating that Sarclisa with VRd induction ...
Medical Dialogues2d
Sanofi Sarclisa approved in EU for transplant-eligible newly diagnosed multiple myeloma
Paris: Sanofi has announced that the European Commission has approved Sarclisa in combination with bortezomib, lenalidomide, ...
Key deals this week: Sanofi, SentinelOne, Marex Group, Synovus Financial, Union Pacific and more
Vertiv (NYSE:VRT) has agreed to acquire the Great Lakes Data Racks & Cabinets family of companies for $200 million. Vicebio, ...
Pharmabiz3d
Sanofi’s Sarclisa receives European approval to treat transplant-eligible newly diagnosed multiple myeloma
Sanofi’s Sarclisa receives European approval to treat transplant-eligible newly diagnosed multiple myeloma: Paris Saturday, July 26, 2025, 09:00 Hrs [IST] Following the positive ...
Contract Pharma4d
Sanofi’s Sarclisa Gains EU Approval for Multiple Myeloma
The European Commission has approved Sanofi’s Sarclisa in combination with bortezomib, lenalidomide, and dexamethasone (VRd) ...
The Pharma Letter4d
Sanofi’s Sarclisa gains new approval in the EU
Following the positive opinion by the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) on ...
Investing.com South Africa4d
Sanofi’s Sarclisa receives EU approval for newly diagnosed multiple myeloma
Sanofi SA (EPA: SASY) announced Friday that its drug Sarclisa has received approval in the European Union for the treatment of transplant-eligible newly diagnosed ...
Press Release: Sanofi’s Sarclisa approved in the EU for the treatment of transplant-eligible newly diagnosed multiple myeloma
Sanofi’s Sarclisa approved in the EU for the treatment of transplant-eligible newly diagnosed multiple myeloma Approval based on GMMG-HD7 phase 3 study demonstrating that Sarclisa with VRd induction ...
PMLiVE1mon
Sanofi’s Sarclisa recommended by CHMP for new multiple myeloma ...
Sanofi’s Sarclisa (isatuximab) has been recommended by the European Medicines Agency’s human medicines committee as part of a combination treatment for newly diagnosed multiple myeloma (MM). The ...
Finanznachrichten1mon
Sanofi: Sarclisa recommended for EU approval by the CHMP to treat ...
Sarclisa recommended for EU approval by the CHMP to treat transplant-eligible newly diagnosed multiple myeloma Recommendation based on GMMG-HD7 phase 3 study demonstrating that Sarclisa with VRd ...
Sanofi: Sanofi's Sarclisa approved in the EU for the treatment of transplant-eligible newly diagnosed multiple myeloma
Sanofi's Sarclisa approved in the EU for the treatment of transplant-eligible newly diagnosed multiple myeloma Approval based on GMMG-HD7 phase 3 study demonstrating that Sarclisa with VRd induction ...